久留米大学 · 医学部

研究キーワード(geometry)・(stratigraphy)・Adverse・Atezolizumab・Bevacizumab・Bilirubin・Cancer・Chemotherapy

ここは公開データのプレビューです。個別の適合理由、連絡角度、保存機能はログイン後に利用できます。

• Dose-Reduction of Bevacizumab in Atezolizumab plus Bevacizumab Therapy Extends Treatment duration with Disease Control in Patients with Hepatocellular Carcinoma.2025 · Oncology, 2025年
• Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan.2025 · Journal of cancer research and clinical oncology, 2025年01月28日
• The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan.2025 · Hepatology international, 2025年02月28日
• Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study.2024 · Liver cancer, 2024年10月

• 公式プロフィール